Kevin Elias, MD, discusses efficacy data from the PRIMA and NOVA trials evaluating niraparib as maintenance therapy in ovarian cancer.
Kevin Elias, MD
Advertisement
Kevin Elias, MD, is a gynecologic oncologist at Cleveland Clinic.
Articles by Kevin Elias, MD
Kevin Elias, MD, discusses the role of olaparib maintenance therapy for patients with BRCA1 and BRCA2-mutated ovarian cancer.
Kevin Elias, MD, discusses the SOLO-1 and SOLO-2 trials, which evaluated olaparib in newly diagnosed and relapsed BRCA-mutated ovarian cancer.
Advertisement
Latest Updated Articles
Dr Elias on Outcomes With Niraparib Maintenance Therapy in Ovarian CancerPublished: October 31st 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5